课题基金 / 基金详情

Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease

Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease
犬克拉伯病的时空心理激素积累和靶向腺相关病毒(AAV)基因治疗
批准号:
10413945
负责人:
Allison M Bradbury
金额:
$24.4万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-05 至 2024-05-31

项目摘要

项目成果

Allison M Bradbury的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 球状细胞白质营养不良症(GLD),通常被称为Krabbe病,是一种使人衰弱且总是致命的疾病 编码水解性溶酶体基因突变引起的儿童神经退行性疾病 半乳糖神经酰胺酶(GALC)。GALC的靶标--细胞毒性精神素的积聚导致损失 少突胶质细胞和雪旺细胞以及广泛的中枢和外周神经系统脱髓鞘。 神经功能障碍在生命的第一年很明显,死亡通常发生在两岁时。 值得注意的是,GLD是一种自然发生的遗传性疾病,为狗建立了繁殖群体; 布拉德伯里博士和她的导师目前维持着这个繁衍生息的群体。GLD犬的疾病进展 详细概括了人类疾病的临床、病理和生化异常。可预测的 疾病进展和寿命(15.7±4.8周龄)允许及时识别病理 治疗干预措施的变化和评价。此外,增加的大小和复杂性 犬脑类似于婴儿的大脑,允许实施临床上相关的方法来 评估疾病进展和治疗策略。长期目标是在这方面进行治疗试验 有价值的大型动物模型,为儿科临床试验提供信息。然而,初步的腺相关病毒 在GLD犬身上进行的(AAV)研究为当前基因治疗方案的关键局限性提供了见解。 申请人认为,进一步阐明阻碍治疗的潜在致病机制至关重要。 在这个特殊的模型中,并随后考虑更多的新的基因治疗方法来治疗这种疾病。 在这里,布拉德伯里博士将使用GLD的犬模型来进一步确定精神病素对 犬少突胶质细胞并利用这些数据开发通过AAV传递的GALC的时空靶向 在这种自然发生的动物模型中治疗疾病的媒介。在K99阶段,她将评估效果 精神病药对犬少突胶质细胞成熟的影响以及这如何影响基因治疗的挽救。她会的 还确定了大脑和脊髓中精神药物的时空积聚及其相互关系 与犬脑中髓鞘成熟的时间有关。在R00阶段,布拉德伯里博士将专注于开发 改善GALC生物分布和靶向性的策略。AAV生物学研究进展 十年通过靶向特定的组织、细胞和受体,提供了更多量身定制的治疗方法。 K99/R00资助机制将提供从NRSA博士后到 独立调查员。除了获得新的实验室技能外,申请人的职业发展将是 通过一个特殊的咨询/指导委员会的专业知识而得到加强。此外,加州大学 宾夕法尼亚州是一所顶级的研究机构,拥有无与伦比的资源和充足的教育和培训 机遇。出色的指导,无与伦比的资源,以及她所在部门的坚定承诺 将加强布拉德伯里博士的候选人资格,并过渡到一个独立的终身教职跟踪教师职位。 好了!
英文摘要
Project Summary/Abstract Globoid cell leukodystrophy (GLD), commonly referred to as Krabbe disease, is a debilitating and always fatal pediatric neurodegenerative disease caused by a mutation in the gene encoding for the hydrolytic lysosomal enzyme galactosylceramidase (GALC). Accumulation of cytotoxic psychosine, a target of GALC, results in loss of oligodendrocytes and Schwann cells and widespread central and peripheral nervous system demyelination. Neurologic dysfunction is apparent in the first year of life and death often occurs by two years of age. Notably, GLD is a naturally occurring hereditary disease in dogs for which a breeding colony was established; Dr. Bradbury and her mentors currently maintain this breeding colony. Disease progression in GLD dogs closely recapitulates clinical, pathological, and biochemical abnormalities of human disease. The predictable disease progression and lifespan (15.7 ± 4.8 weeks of age) allow for timely identification of pathological changes and evaluation of therapeutic interventions. Furthermore, the increased size and complexity of the canine brain are similar to that of an infant allowing for implementation of clinically relevant methods to evaluate disease progression and therapeutic strategies. The long-term goal is to conduct therapy trials in this valuable large animal model to inform pediatric clinical trials. However, preliminary adeno-associated virus (AAV) studies in the GLD dog have provided insights to critical limitations of current gene therapy protocols. The applicant believes that it is vital to further elucidate underlying pathogenic mechanisms hindering therapy in this particular model and subsequently consider more novel gene therapy approaches to treat this disease. Herein Dr. Bradbury will use the canine model of GLD to further define the neurotoxic effect of psychosine on canine oligodendrocytes and use these data to develop temporospatial targeting of GALC delivered via AAV vectors to treat disease in this naturally occurring animal model. In the K99 phase she will evaluate the effect of psychosine on canine oligodendrocyte maturation and how this impacts rescue by gene therapy. She will also determine the temporospatial accumulation of psychosine in the brain and spinal cord and how it relates to the timing of myelin maturation in the canine brain. In the R00 phase Dr. Bradbury will focus on developing strategies to improve GALC biodistribution and targeting of pyschosine. Advances in AAV biology over the past decade provide for more tailored therapeutic approaches by targeting specific tissues, cells, and receptors. The K99/R00 funding mechanism will provide a necessary transition from NRSA postdoctoral fellow to an independent investigator. In addition to gaining new laboratory skills, the applicant's career development will be enhanced by the expertise of an exceptional advisory/mentoring committee. Additionally, the University of Pennsylvania is a top tier research institution with unparalleled resources and ample educational and training opportunities. The outstanding mentoring, unmatched resources, and strong commitment from her department will strengthen Dr. Bradbury's candidacy for, and transition to, an independent tenure-track faculty position. !
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease
Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease
Lentiviral-mediated Hematopoietic Stem Cell Gene Therapy for Canine Globoid Cell Leukodystrophy
  • 批准号:
    9300725
  • 项目类别:
  • 资助金额:
    $5.92万
  • 财政年份:
    2016
  • 负责人:
    Allison M Bradbury
  • 依托单位:
海外基金